B7-33 10mg

Introducing B7-33, a groundbreaking synthetic peptide that harnesses the extraordinary power of human relaxin-2 to combat fibrosis and protect heart health. This 26-amino acid peptide is meticulously designed to target the Relaxin Family Peptide Receptor 1 (RXFP1), promoting selective intracellular signaling pathways that catalyze heart and tissue rejuvenation. Unlike its native counterpart, B7-33 effectively phosphorylates ERK1/2, ensuring potent anti-fibrotic effects while minimizing unwanted hormone-like interactions.

In preclinical studies, B7-33 has demonstrated remarkable capabilities in reducing myocardial stiffness and shielding cardiomyocytes from damage, significantly improving outcomes after myocardial infarction. Its potential to diminish excessive collagen deposition in key organs — including the heart, lungs, and liver — offers an innovative approach to managing fibrosis without severe side effects. Researchers are actively exploring enhanced lipidated and structurally altered variants of B7-33 to boost its stability and efficacy in human serum, ensuring it remains at the forefront of cardiovascular and organ health.

With B7-33, you’re not just investing in a peptide; you’re embracing the future of therapeutic interventions to restore tissue health and heart function. Experience the advantages of a targeted, science-backed solution that promises to redefine healing on a cellular level.

B7-33, a meticulously synthesized peptide comprising 26 amino acids, is derived from the B-chain of human relaxin-2, representing a paradigm shift in therapeutic applications targeting fibrotic and cardiovascular pathologies. This agent has garnered extensive scrutiny in preclinical contexts due to its pronounced anti-fibrotic and cardioprotective capacities, functioning as a selective agonist of the Relaxin Family Peptide Receptor 1 (RXFP1). Notably, B7-33 diverges from the archetypal native relaxin by virtue of its structural integrity as a single-chain molecule that orchestrates biased intracellular signaling cascades. This specificity facilitates the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), thereby engendering a strategic attenuation of off-target, hormone-like interactions that commonly complicate the pharmacodynamics of peptide therapeutics.

In the realm of cardiac health, empirical investigations illustrate B7-33’s ability to ameliorate myocardial stiffness and confer cytoprotective effects on cardiomyocytes, particularly in the context of post-myocardial infarction remodeling. The modulation of adverse cardiac remodeling through the strategic application of B7-33 underscores its potential to mitigate the progression of heart failure, presenting a compelling case for its incorporation into therapeutic regimens. Concurrently, the peptide is scrutinized for its efficacy in curtailing excessive collagen deposition in various organ systems, including the myocardium, lungs, and liver, demonstrating a remarkable capacity to reduce organ fibrosis without incurring significant adverse effects.

Furthermore, the stability and biocompatibility of B7-33 remain critical focal points in ongoing research endeavors. Investigative trajectories are currently directed towards the development of lipidated and structurally modified analogs of B7-33, aimed at enhancing its persistence in human serum and optimizing its pharmacokinetic profile. Such endeavors are predicated on the hypothesis that strategic alterations can yield improved therapeutic indices, paving the way for the translation of B7-33 into clinical practice as a robust and versatile therapeutic modality for fibrotic and cardiovascular diseases.